Stock News

A Reversal for Arena Pharmaceuticals Inc (NASDAQ:ARNA) Is Near. The Stock Has Decrease in Shorts

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

The stock of Arena Pharmaceuticals Inc (NASDAQ:ARNA) registered a decrease of 5.74% in short interest. ARNA’s total short interest was 2.84M shares in November as published by FINRA. Its down 5.74% from 3.01M shares, reported previously. With 423,200 shares average volume, it will take short sellers 7 days to cover their ARNA’s short positions.

The stock decreased 2.47% or $0.92 during the last trading session, reaching $36.27. About 391,654 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 66.28% since November 10, 2017 and is uptrending. It has outperformed by 50.66% the S&P500.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.79 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

More notable recent Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news were published by: Nasdaq.com which released: “Factors of Influence in 2018, Key Indicators and Opportunity within Meritor, Fred’s, Arena Pharmaceuticals …” on October 15, 2018, also Seekingalpha.com with their article: “Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q3 2018 Results – Earnings Call Transcript” published on November 08, 2018, Benzinga.com published: “34 Stocks Moving In Friday’s Pre-Market Session” on November 09, 2018. More interesting news about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were released by: Seekingalpha.com and their article: “Celgene Does Not Have A Growth Catalyst – Cramer’s Lightning Round (11/6/18)” published on November 07, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie” with publication date: November 07, 2018.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*